Rebif

Rebif Indications/Uses

interferon beta-1a

Manufacturer:

Merck

Distributor:

Apex Pharma Marketing
Full Prescribing Info
Indications/Uses
Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see Pharmacology: Pharmacodynamics under Actions).
Rebif 22 mcg:
Treatment of relapsing multiple sclerosis.
In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see Pharmacology: Pharmacodynamics under Actions).
Rebif 44 mcg: Treatment of patients with single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing relapsing multiple sclerosis (see Pharmacology: Pharmacodynamics under Actions); patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see Pharmacology: Pharmacodynamics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in